Published congress abstracts

  1. Duchnowska R, Czartoryska-Arłukowicz B, Radecka B, Szostakiewicz B, Karpinska A, Dziadziuszko R, Szczylik C. Brain metastases in HER-2 positive metastatic breast cancer (MBC) patients. Eur J Cancer Suppl 2006; 4: 165.

  2. Duchnowska R, Czartoryska-Arlukowicz B, Radecka B, Szostakiewicz B, Sosinska K, Karpinska A, Dziadziuszko R, Kubiatowski T, Staroslawska E, Szczylik C. Predictors of brain relapse in HER-2 positive metastatic breast cancer (MBC) patients (pts). J Clin Oncol 2006; 24 (Supl): abst. 10508.

  3. Duchnowska R, Czartoryska-Arlukowicz B, Radecka B, Szostakiewicz B, Karpinska A, Dziadziuszko R et al. Brain metastases in HER-2 positive metastatic breast cancer (MBC) patients. Eur J Cancer (suppl) 2006; 4: 165-166.

  4. Duchnowska R. Brain metastases in breast cancer patients. Nowotwory J Oncol 2006; 56 (suppl 4): 45.

  5. Duchnowska R, Czartoryska-Arlukowicz B, Radecka B, Szostakiewicz B, Sosinska K, Karpinska A, Dziadziuszko R, Kubiatowski T, Staroslawska E, Szczylik C. Brain metastases in HER2-positive advanced breast cancer patients. Nowotwory J Oncol 2006; 56 (suppl 4): 81.

  6. Duchnowska R, Czartoryska-Arlukowicz B, Radecka B, Szostakiewicz B, Sosinska K, Karpinska A, Dziadziuszko R, Kubiatowski T, Staroslawska E, Szczylik C. Risk factors for brain relapse in HER-2 positive metastatic breast cancer patients (pts). Proc 1st Interconference Breast Cancer Meeting in Sarajevo 2007; 60.

  7. Duchnowska R, Czartoryska-Arlukowicz B, Radecka B, Szostakiewicz B, Sosinska K, Karpinska A, Dziadziuszko R, Staroslawska E, Kubiatowski T, Szczylik C. Prediction of brain relapse (BR) in HER-2 positive metastatic breast cancer (MBC) patients. Eur J Cancer Suppl 2007;5:213.

  8. Duchnowska R, J. Jassem, C. Szczylik, G.W. Sledge, L. Li,Jr., B. Czartoryska-Arlukowicz, B. Radecka, K. Sosinska, P. Steeg, S. Badve. Prediction of brain relapse by gene expression analysis in HER2-positive metastatic breast cancer patients. Eur J Cancer Suppl 2008; 6 (Supl):193s.

  9. Duchnowska R, Jassem J, Thorat M, Morimiya A, Li L, Sledge GW Jr, Biernat W, Szczylik C, Steeg P, Badve S. Gene expression analysis for prediction of early brain metastasis in HER2-positive breast cancer patients. J Clin Oncol 2008; 26 (suppl): 45s.

  10. Duchnowska R, Jassem J, Shen C, Thorat M, Li L, Morimiya A, Zhao Q, Biernat W, Mandat T, Staszkiewicz R, Och W, Szostak W, Gugala K, Trojanowski T, Czartoryska-Arlukowicz B, Szczylik C, Nakshatri H, Steeg P, Sledge G, Badve S. Molecular characteristics of matched brain metastasis (BM) versus the primary breast cancer (PBC). Abst 31st Annual San Antonio Breast Symposium 2008; 164s (abst. 2028).

  11. Duchnowska R, Siemiątkowska A, Grala B, Smoter Tujakowski J. Selection criteria for erlotinib therapy in advanced non-small-cell lung cancer (NSCL) based on clinical and molecular factors. Presentation of cases and conclusions. Onkol Prakt Klin, 2008: 4: B30.

  12. Duchnowska R, Jassem J, Shen C, Thorat M, Li L, Morimiya A, Zhao Q, Biernat W, Mandat T, Staszkiewicz R, Och W, Szostak W, Gugała K, Trojanowski T, Czartoryska-Arlukowicz B, Szczylik C, Nakshatri H, Steeg P, Sledge GW, Badve S. Molecular features of matched brain metastasis (BM) versus the primary breast cancer (PBC). Abst Book 6th Central European Oncology Conference, Opatia, 2009; 93.

  13. Duchnowska R, Szostakiewicz B, Jankowski T, Arlukowicz-Czartoryska B, Wysocki PJ, Huang W, Bates MP, Weidler J, Haddad M, Jassem J. Correlation between quantitative HER2 protein level and the risk of brain metastasis (BM) in patients (pts) with metastatic breast cancer (MBC) treated with trastuzumab-containing therapy. J Clin Oncol 28:15s, 2010 (suppl; abstr. 1030).

  14. Duchnowska R, Szostakiewicz B, Jankowski T, Arlukowicz-Czartoryska B, Wysocki W, Huang W, Bates MP, Weidler J, Haddad M, Jassem J. Correlation between quantitative HER2 protein level and the risk of brain metastasis (BM) in patients (pts) with metastatic breast cancer (MBC) treated with trastuzumab-containing therapy. Nowotwory J Oncol 2011; 61 (suppl. 2):36-37.

  15. Minuti G, Roncalli M, Fabi A, Landi L, Jassem J, Duchnowska R, Biernat W, Sarnelli R, Varella-Garcia M, Cappuzzo F. MET increased gene copy number and trastuzumab efficacy in HER2 positive metastatic breast cancer patients: preliminary results of an international retrospective collaborative study. Ann Oncol 2011; 22 (suppl. 2; abstr. 31P).

  16. Jassem J, Duchnowska R, Biernat W, Evans LM, Fitzgerald DP, Woditschka S, Szostakiewicz B, Mandat T, Jarosz B, Trojanowski T, Szubstarski F, Arlukowicz-Czartoryska B, Staszkiewicz R, Szostak B, Olszewski W, Steeg SP, Li L, Sledge GW, Palmieri D, Badve SS. The neuronal cell adhesion molecule L1CAM as a therapeutic target in breast cancer. J Clin Oncol 2011: 29 (suppl; abstr. e21138).

  17. Duchnowska R, Jassem J, Szutowicz E, Biernat W, Jankowski T, Och W, Staszkiewicz R, Chudzik M, Rogowski W, Flores N, Woditschka S, Li L, Goswami C, Thorat MA, Gokmen-Polar Y, Sledge GW, Steeg PS, Palmieri D, Badve SS. RAD51 and brain metastases (BM) in patients (pts) with HER2+ breast cancer. J Clin Oncol 2011; 29 (suppl; abstr. 634).

  18. Audet R, Duchnowska R, Adamowicz K, Zok J, Rogowski W, Litwiniuk MM, Debska S, Jaworska M, Foszczynska-Kloda M, Kulma-Kreft M, Zabkowska K, Shen C, Edgerton S, Nielsen KV, Thor AD, Chang JCN, Miller K, Jassem J, Sledge GW, Leyland-Jones B. Thymidilate synthase gene copy number as predictive marker of capecitabine efficacy in patients with breast cancer. J Clin Oncol 2011; 29 (suppl; abstr. 10629).

  19. Biernat W, Duchnowska R, Szostakiewicz B, Sperinde J, Haddad M, Paquet A, Lie Y, Weidler J, Huang W, Winslow J, Jankowski T, Arlukowicz-Czartoryska B, Wysocki PJ, Foszczynska-Kloda M, Radecka B, Litwiniuk MM, Debska S, Bates M, Jassem J. Quantitative measurements of p95HER2 (p95) and total HER2 (H2T) protein expression in patients with trastuzumab-treated, metastatic breast cancer (MBC): Independent confirmation of clinical cutoffs. J Clin Oncol 2011; 29 (suppl; abstr. 586).

  20. Duchnowska R, Szostakiewicz B, Jankowski T, Arlukowicz-Czartoryska B, Wysocki PJ, Huang W, Bates MP, Weidler J, Haddad M, Jassem J. High HER2 protein level is associated with increased risk of brain metastasis (BM) in patients with metastatic breast cancer (MBC) treated with trastuzumab-containing therapy. Abst Book 7th Central European Oncology Conference, Opatia, 2011; 59.

  21. Duchnowska R, Szostakiewicz B, Dziadziuszko R, Mandat T, Olszewski W, Jarosz B, Czartoryska-Arłukowicz M, Radecka B, Biernat W, Jassem J. Receptor conversion in breast cancer brain metastases (BM). Eur J Cancer 2011; 47 (suppl. 1): S 355.

  22. Duchnowska R, Biernat W, Szostakiewicz B, Sperinde J, Piette F, Haddad M, Paquet A, Lie Y, Czartoryska-Arłukowicz M, Wysocki P, Jankowski T, Radecka B, Foszczyńska-Kłoda M, Litwiniuk M, Dębska S, Weidler J, Huang W, Buyse M, Bates M, Jassem J. Correlation between quantitative HER2 protein expression and risk of brain metastases in HER2-positive advanced breast cancer patients receiving trastuzumab-containing therapy. Cancer Res 2011; 71(suppl): 291s.

  23. Audet R, Shen C, Duchnowska R, Adamowicz K, Zok J, Rogowski W, Litwiniuk MM, Debska S, Jaworska M, Foszczynska-Kloda M, Kulma-Kreft M, Ząbkowska K, Jassem J, Edgerton S, Nielsen KV, Thor AD, Chang JCN, Miller K, Sledge GW, Leyland-Jones B. Gene copy number and expression of TYMP and TYMS are predictive of outcome in breast cancer patients treated with capecitabine. Cancer Res 2011; 71(suppl): 541s.

  24. Minuti G, Duchnowska R, Jassem J, Roncalli M, O’Brien T, Fabi A, Landi L, Di Marsico R, Biernat W, Czartoryska-Arłukowicz B, Jankowski T, Zuziak D, Zok J, Szostakiewicz B, Foszczyńska-Kłoda M, Tempińska-Szałach A, Rossi E, Varella-Garcia M, Cappuzzo F. MET and hepatocyte growth factor (HGF) increased gene copy number is associated to trastuzumab failure in HER2 positive metastatic breast cancer (MBC). Cancer Res 2011; 71(suppl), 552s.

  25. Duchnowska R, Jassem J, Pankaj Goswami C, Gokmen-Polar Y, Li L, Thorat M.A, Flores N, Hua E, Woditschka S, Palmieri D, Steinberg S.M., Biernat W, Sosinska-Mielcarek K, Szostakiewicz B, Czartoryska-Arlukowicz B, Radecka B, Tomasevic Z, Sledge G.W., Steeg P.S., Badve S.S, Polish Brain Metastasis Consortium.13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer. J Clin Oncol 2012; 30 (suppl; abstr 505).

  26. Audet R, Shen C, Willis S, Duchnowska R, Adamowicz K, Zok J, Rogowski W, Litwiniuk M, Debska S, Jaworska M, Foszczynska-Kloda M, Kulma-Kreft M, Zabkowska K, Jassem J, Edgerton S, Thor A, Miller K, Sledge G, Leyland-Jones B. Gene expression combined with gene set enrichment analysis to identify markers of vinorelbine efficacy in breast cancer patients. J Clin Oncol 2012;30 (suppl, abstr. e21099).

  27. Biernat W, Duchnowska R, Trojanowski T, Mandat T, Kowalczyk A, Czartoryska-Arlukowicz B, Radecka B, Jarosz B, Staszkiewicz R, Kalinka-Warzocha E, Chudzik M, Sperinde J, Haddad M, Paquet A, Lie Y, Winslow JW, Weidler JM, Huang W, Petropoulos CJ, Jassem J, Polish Brain Metastasis Consortium. Quantitative HER2 levels and steroid receptor expression in primary breast cancers and in matched brain metastases. J Clin Oncol 2012; 30 (suppl; abstr. 603).

  28. Woditschka S, Palmieri D, Duchnowska R, Jassem J, Badve S, Sledge GW, Jr., Steeg PS. Overexpression of RAD51 promotes brain metastases from breast cancer. Cancer Res 2012;72 (suppl 1, abstr. 5306).

  29. Duchnowska R, Jassem J, Pankaj Goswami C, Gokmen-Polar Y, Li L, Thorat MA, Morimiya A, Flores N, Hua E, Woditschka S, Palmieri D, Steinberg SM, Biernat W, Sosinska-Mielcarek K, Szostakiewicz B, Czartoryska-Arlukowicz B, Radecka B, Tomasevic Z, Sledge GW, Steeg PS, Badve SS. 13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer. Nowotwory J Oncol 2012; 62: 128 (suppl 2, O17).

  30. Sosińska-Mielcarek K, Winczura P, Duchnowska R, Badzio A, Majewska H, Lakomy J, Pęksa R, Pieczyńska B, Radecka B, Dębska S, Zok J, Rogowski W, Strzelecka M, Kulma-Kreft M, Błaszczyk P, Litwiniuk M, Jesień-Lewandowicz E, Rutkowski T, Jaworska-Jankowska M, Adamowicz K, Foszczyńska-Kłoda M, Biernat W, Jassem J. Correlation between expression of selected proteins in primary tumor and high risk of brain metastasis in breast cancer patients. Nowotwory J Oncol 2012; 62: 128 (suppl 2, O18).

  31. Duchnowska R, Trojanowski T, Mandat T, Och W, Czartoryska-Arłukowicz B, Radecka B, Olszewski W, Szubstarski F, Kozłowski W, Jarosz B, Rogowski W, Kowalczyk A, Limon J, Biernat W, Jassem J. Receptor conversion (steroid and HER2) in breast cancer brain metastases. Nowotwory J Oncol 2012; 62: 235 (suppl 2, P1840).

  32. Duchnowska R, Biernat W, Trojanowski T, Mandat T, Kowalczyk A, Czartoryska-Arłukowicz B, Radecka B, Jarosz B, Staszkiewicz R, Kalinka-Warzocha E, Chudzik M, Sperinde J, Haddad M, Paquet A, Lie Y, Winslow J, Weidler J, Huang W, Petropoulos C, Jassem J. Quantitative HER2 levels and steroid receptor expression in primary breast cancers and in matched brain metastases. Nowotwory J Oncol 2012;62:235 (suppl 2, P1849).

  33. Winczura P, Sosińska-Mielcarek K, Duchnowska R, Badzio A, Lakomy J, Majewska H, Pęksa R, Pieczyńska B, Radecka B, Dębska S, Żok J, Rogowski W, Strzelecka M, Kulma-Kreft M, Błaszczyk P, Litwiniuk M, Jesień-Lewandowicz E, Rutkowski T, Jaworska-Jankowska M, Adamowicz K, Foszczyńska-Kłoda M, Biernat W, Jassem J. Molecular preditors of bone metastases in breast cancer patiets. Nowotwory J Oncol 2012:62; 238 (suppl 2, P1941).

  34. Duchnowska R. Biology of brain metastases. Nowotwory J Oncol 2012:62; 69 (suppl 2), abstr. W123.

  35. Duchnowska R. Gene signature to predict rapid development of brain metastases in HER2-positive advanced breast cancer patients. 2nd Annual Brain Metastases Research and Emerging Therapy Conference, 5 September 2012; Palais des rts, Parc Chanot, Marseilles.

  36. Duchnowska R, Sperinde J, Leitzel K, Szostakiewicz B, Paquet A, Ali SM, Jankowski T, Haddad M, Fuchs E-M, Arlukowicz-Czartoryska B, Winslow J, Singer C, Wysocki PJ, Lie Y, Horvat R, Foszczynska-Kloda M, Petropoulos C, Radecka B, Litwiniuk M, Debska S, Weidler J, Huang W, Biernat W, Kostler WJ, Jassem J, and Lipton A. Correlation of quantitative p95HER2 and total HER2 levels with clinical outcomes in a combined analysis of two cohorts of trastuzumab-treated metastatic breast cancer patients. Cancer Res 2012; 72: P2-10-31.

  37. Winczura P, Sosinska-Mielcarek K, Duchnowska R, Badzio A, Lakomy J, Majewska H, Peksa R, Pieczynska B, Radecka B, Debska S, Zok J, Rogowski W, Strzelecka M, Kulma-Kreft M, Blaszczyk P, Litwiniuk M, Jesien-Lewandowicz E, Rutkowski T, Jaworska-Jankowska M, Adamowicz K, Foszczynska-Kloda M, Biernat W, and Jassem J. Molecular factors associated with bone metastases in breast cancer patients. Cancer Res 2012; 72: P3-13-03.

  38. Sosinska-Mielcarek K, Winczura P, Duchnowska R, Badzio A, Majewska H, Lakomy J, Peksa R, Pieczynska B, Radecka B, Debska S, Zok J, Rogowski W, Strzelecka M, Kulma-Kreft M, Blaszczyk P, Litwiniuk M, Jesien-Lewandowicz E, Rutkowski T, Jaworska-Jankowska M, Adamowicz K, Foszczynska-Kloda M, Biernat W, and Jassem J. The risk of brain metastases according to expression of selected immunohistochemical markers in primary breast cancers. Cancer Res 2012; 72: P3-12-09.

  39. Duchnowska R, Sperinde J, Chenna A, Haddad M, Lie Y, Weidler J, Huang W, Wilson J, Jankowski T, Czartoryska-Arłukowicz B, Wysocki PJ, Foszczyńska-Kłoda M, Radecka B, Litwiniuk MM, Zok J, Wiśniewski M, Zuziak D, Biernat, Jassem J. Quantitative measurements of p95HER2 (p95) protein expression in tumors from patients with metastatic breast cancer (MBC) treated with trastuuzmab: independent confirmation of the p95HER2 clinical cotoff. J Clin Oncol 2013; 31 (suppl.) abstr. 604.

  40. Duchnowska R, Sperinde J, Chenna A, Huang W, Weidler JM, Winslow J, Haddad M, Paquet A, Lie Y, Trojanowski T, Mandat T, Kowalczyk A, Czartoryska-Arłukowicz B, Radecka B, Jarosz B, Staszkiewicz R, Kalinka-Warzocha E, Chudzik M, Biernat W, Jassem J. Quantitative p95HER2 levels in primary breast cancers and in matched brain metastases. Cancer Res 2013; P6-11-07; SABCS 2013-P6-11-07.

  41. Jassem J, Palmieri D, Duchnowska R, Hua E, Qian Y, Biernat W, Sosińska-Mielcarek K, Gril B, Stark A, Hewitt S, Liewehr DJ, Steinberg SM, Steeg PS. Profound prevention of experimental brain metastases of breast cancer by temozolomide in a MGMT-dependent manner. Cancer Res 2013; P6-11-04.

  42.  Duchnowska R, Jassem J. Pre-clinical model in brain metastases: the role of temozolomide. 3rd Annual Brain Metastases Research and Emerging Therapy Conference, 5 September 2012; Palais des rts, Parc Chanot, Marseilles. Duchnowska R, Wysocki PJ, Korski K, Czartoryska-Arlukowicz B, Niwińska A, Orlikowska M, Radecka B, Studzinski M, Demlova R, Ziołkowska B, Merdalska M, Hajac Ł, Myśliwiec P, Zuziak D, Dębska S, Lang I, Foszczynska-Kłoda M, Kowalczyk A, Biernat W, Jassem J, Central and East European Oncology Group;Immunohistochemical (IHC) prediction of lapatinib efficacy in HER2-positive advanced breast cancer patients. J Clin Oncol 2014; 32:5s (Supl.) abstr. 639.

  43. Jassem J, Duchnowska R. Brain metastases phenotype heterogeneity. 5th Annual Brain Metastases Research and Emerging Therapy Conference, October 2-3 2015, Marseille, France

  44. Duchnowska R, Peksa R, Radecka B, Mandat T, Trojanowski T, Jarosz B, Czartoryska-Arlukowicz B, Olszewski WP, Och W, Kalinka-Warzocha E, Kozłowski W, Kowalczyk A, Loi S, Biernat W, Jassem J. Immune response in breast cancer brain metastases and their microenvironment. 5th Annual Brain Metastases Research and Emerging Therapy Conference, October 2-3 2015, Marseille, France

  45. Duchnowska R, Jarzab M, Zebracka J, Matkowski R, Kowalczyk A, Radecka B, Foszczynska-Kloda M, Musolino A, Czartoryska-Arlukowicz B, Litwiniuk MM, Szablowska-Siwik S, Karczmarek-Borowska B, Sosinska-Mielcarek K, Chmielowska E, Olszewski WP, Patera J, Zawrocki A, Rusinek D, Jassem J, Biernat W, on behalf of the Polish Brain Metastasis Consortium; Brain metastasis (BM) prediction by transcriptomic profiling in triple-negative breast cancer (TNBC). J Clin Oncol 34, 2016 (suppl; abstr 1076).

  46. Duchnowska R, Jarząb M, Żebracka J, Matkowski R, Kowalczyk A, Radecka B, Foszczyńska-Kłoda M, Musolino A, Czartoryska-Arłukowicz B, Litwiniuk M, Szabłowska-Siwik S, Karczmarek-Borowska B, Sosińska-Mielcarek K, Chmielewska E, Olszewski WP, Patera J, Zawrocki A, Rusinek D, Jassem J, Biernat W. Brain metastasis (BM) prediction by transcriptomic profiling in triple-negative breast cancer (TNBC). Nowotwory Journal of Oncology 2016, wyd. spec., s.13.

  47. Duchnowska R, Sperinde J, Czartoryska-Arłukowicz B, Mysliwiec P, Winslow J, Radecka B, Petropoulos C, Demlova R, Orlikowsks M, Kowalczyk A, Lang I, Ziólkowska B, Dębska-Szmich S, Merdalska M, Grela-Wojewoda A, Żawrocki A, Biernat W, Huang W, Jassem J. Predictive value of quantitative HER2 and HER3 levels combined with downstream signaling markers in HER2-positive advanced breast cancer patients treated with lapatinib. 40th Annual SABCS, December 2017.

 

Contact

home
Medical University of Gdańsk
Department of Oncology and Radiotherapy
7 Dębinki Street
80-211 Gdańsk, Poland
 
email
Phone: +48 58 349 2282
Fax: +48 58 349 22 44
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.